Pediatric acute myeloid leukemia patients with i(17)(q10) mimicking acute promyelocytic leukemia: Two case reports

Hong-Xia Yan, Wei-Hua Zhang, Jin-Quan Wen, Yan-He Liu, Bao-Juan Zhang, A-Duo Ji

Abstract

BACKGROUND
Chromosome i(17)(q10) abnormality is mainly associated with chronic myeloid leukemia (CML), myelodysplastic syndrome/myeloproliferative tumors (MDS/MPD), and acute myeloid leukemia (AML). The role of i(17)(q10) in AML is still unknown, the differences between AML and acute promyelocytic leukemia (APL)-like AML with i(17)(q10) need more research. This study aimed to investigate the clinical characteristics and laboratory evidence of 2 AML cases with i(17)(q10), similar to APL phenotype.

CASE SUMMARY
Both pediatric patients were males; case 1 had newly diagnosed AML, and case 2 showed relapsed tumor after 1 year of drug withdrawal. Bone marrow cell morphology, chromosome karyotype analysis, Fully-instrumented submersible housing test, immunological assays, molecular biological methods, and blood tumor panoramic gene test were performed. All-trans retinoic acid (ATRA) combined with arsenic acid (As2O3) were used in the first course of treatment. Bone marrow was dominated by abnormal promyelocytic granulocytes. Karyotype test revealed i(17)(q10) isochromosome. Immunological phenotype mainly included positive expressions of CD9, CD13, CD33, and CD38. Case 1 suffered intracranial hemorrhage after re-chemotherapy and died on D162. For case 2, on D145 and D265, bone marrow promyelocytic granulocytes accounted for 2%. Flow cytometric residual lesion detection showed no abnormal immuno-
phenotype cells. The copy number of WT1 gene in two cases were 1087 and 1010, respectively, and the expression rates were 55.29% and 59.5%, respectively.

CONCLUSION
ATRA, As2O3, and chemotherapy may be ineffective in treating APL-like AML with i(17)(q10) but without t(15;17) and PML-RARA fusion gene.

Key Words: Chromosome; i(17)(q10); Gene mutations; Acute promyelocytic leukemia; Acute myeloid leukemia; Case report

INTRODUCTION
Chromosome i(17)(q10) abnormality is described as any unreasonable damage or breakage of the centromeres of chromosome 17, resulting in absence of the short arm and an iso-arm of the long arm[1]. Isochromosome 17 i(17)(q10) is mainly associated with chronic myeloid leukemia (CML)[2,3], myelodysplastic syndrome/myeloproliferative tumors (MDS/MPD)[4-6], and acute myeloid leukemia (AML)[6, 7]. Genetic mutation analysis showed that 95% of patients with chromosome karyotype i(17)(q10) carried at least one mutation, and on average three mutations. The three most commonly mutated genes were ASXL1 (66%), SRSF2 (65%), and SETBP1 (48%)[8,9]. In acute promyelocytic leukemia (APL), chromosome karyotype i(17)(q10) was often accompanied by t(15;17) and PML-RARA fusion gene with an incidence of 1.9% and 4.1%, respectively[10,11]. APL children with i(17)(q10) have poor prognosis[12]. In a group study of 478 children with AML, chromosome karyotype analysis showed only one i(17)(q10) abnormality case, without morphological description and prognostic evaluation[13]. A 10-year-old African Black APL child carrying i(17)(q10) karyotype but without t(15;17) abnormality, who was in serious condition at admission, did not get tumor remission after treatment, and died within 2 wk[14]. A Chinese i(17)(q10) AML adult with a similar phenotype to APL was reported[15]. In the present case study, we treated 1 AML child with i(17)(q10) and 1 AML child with i(17)(q10) and (14)(p11) who had a phenotype similar to APL in our department. These two cases were investigated and followed up, and their clinical significance was discussed.

CASE PRESENTATION
Chief complaints
Case 1: A 3-year-old boy of Han nationality, was admitted to the Pediatric Hematology Department of Xianyang Caihong Hospital, China on December 19, 2016. The boy had paleness and fever for more than half a month, as well as exophthalmos and pain in the right knee joint due to unknown reasons for two weeks.

Case 2: A 12-year-old Han boy was admitted to our hospital with a history of a pale complexion for one month and skin bleeding for 10 d.
**History of present illness**

**Case 1:** He had a fever of 38.2 °C, moderate anemia, scattered red bleeding spots on the skin, protruded eyeballs, and no swelling of the superficial lymph nodes. Initial blood tests showed the following: Hb 75 g/L, white blood cell (WBC) count $5.82 \times 10^9/L$, and platelet (PLT) count $73 \times 10^9/L$.

**Case 2:** He had moderate anemia and bleeding spots on the skin and mucosa throughout the body. Initial blood test results showed the following: Hb 68 g/L, WBC count $17.53 \times 10^9/L$, and PLT count $60 \times 10^9/L$.

**History of past illness**

**Case 1:** There is no history of past illness.

**Case 2:** He was diagnosed with APL 3 years ago in a local hospital based on bone marrow morphology and immunological classification, with negative PML-RARa fusion gene at the time of diagnosis. The patient received all-trans retinoic acid (ARAT) and arsenic trioxide (ATO) as induction therapy, and bone marrow examination showed no tumor remission on D29. He then received three cycles of consolidation therapy (DA, HA, and MA regimen) and maintenance therapy, bone marrow evaluation showed complete remission, and the treatment was stopped.

**Personal and family history**

**Case 1:** He had been in good health condition, with no family history of inherited blood disorder, no history of tumor-associated genetic abnormalities, and no history of drug or food allergies.

**Case 2:** There is no personal and family history.

**Physical examination**

**Case 1:** Upon examination, he had a fever of 38.2 °C, moderate anemia, scattered red bleeding spots on the skin, protruded eyeballs, and no swelling of the superficial lymph nodes. On auscultation, his heart and lung were normal, and the liver and spleen were not examined.

**Case 2:** He had moderate anemia and bleeding spots on the skin and mucosa throughout the body. Auscultation of the heart and lung showed no abnormalities. Subcostal areas of the liver and spleen were not examined.

**Laboratory examinations**

A volume of 0.1 mL bone marrow fluid was extracted from the posterior superior iliac spine (sampling was very difficult), a bone marrow smear was prepared and submitted for examination. Chromosome G-banding karyotype analysis: 3 mL of sterile bone marrow fluid was taken from the patient, and g-banding technique was employed to detect the chromosomes in trypsin-digested short-term cell culture. Karyotype results were analyzed according to the international system for human cytogenetic nomenclature (ISCN, 1991).

Immunophenotype: 2 mL of bone marrow fluid with heparin anticoagulant was obtained, $5 \times 10^5-5 \times 10^6$ /mL cells were isolated using FACSort flow cytometry (BD Biosciences) and analyzed with CellQuest software. The expression levels of leukemia related antigens in the cell population were analyzed and calculated. Monoclonal antibodies used included HLA-DR, CD2, CD3, CD4, CD7, CD8, CD9, CD11b, CD13, CD14, CD15, CD16, CD19, CD22, CD33, and CD34 Labeled by FITC, PE, and PerCP, or APC-CD38, CD56, CD64, CD71, CD117, CD123, and MPO. All antibodies were purchased from BD Biosciences.

PML-RARa fusion gene was detected by real-time quantitative PCR: A volume of 2 mL bone marrow fluid with heparin anticoagulant was collected to isolate the mononuclear cells, and total DNA of mononuclear cells was extracted.

**Imaging examinations**

There is no imaging examinations.

---

**FINAL DIAGNOSIS**

Acute promyelocytic leukemia -like acute myeloid leukemia with i(17)(q10).

---

**TREATMENT**

Phase I: Two children were treated with ATAR combined with ATO to induce remission: ATAR (30 mg/M2/d), divided 3 times, orally, D1-30; ATO (0.02 mg/Kg), 1 time/day, intravenous infusion, D1-28.
Then they were treated with low molecular weight heparin anticoagulant correction therapy based on the coagulation test. Bone marrow cell morphology and leukocyte residual lesions were detected on D29. Blood WBC count was 27.53 × 10⁹/L. Considering the possibility of retinoic acid syndrome, dexamethasone tablets were administered orally at 1.5 mg/time, 3 times a day. With fever regression, WBC was reduced to 12.27 × 10⁹/L on D7. Case 2 showed fever on D2 of treatment, with a temperature of 38.5 °C, and still had a fever on D3. Blood routine test showed a WBC count of 27.53 × 10⁹/L. Considering the possibility of the retinoic acid syndrome, dexamethasone tablet was taken 1.5 mg/time, 3 times a day. With fever regression, WBC decreased to 12.27 × 10⁹/L in D7.

Phase II: On D33, case 1 was treated with the DAE regimen, which including the following: DNR (40 mg/M²/d), D1, 3 and 5, intravenous infusion, once a day; Ara-c (200mg/M²/d), D 1-7, q12h, subcutaneous injection; and Vp-16 /E (100mg/M²/d), D 5, 6, 7, intravenous infusion, once a day. Reexamination of bone marrow cell morphology on D 65 showed no remission. The pediatric patient gave up treatment and discharged themselves. On D154, he came to the hospital again with fatigue, sallow complexion, skin hemorrhagic spots, bone pain, and eyeball herniation. Bone marrow examination showed 85% abnormal promyelocytic granulocytes. D156 Chemotherapy with MAH protocol: M (10 mg/M²/d), D1, 2 and 3; A (200 mg/M²/d), D1-7, q12h, subcutaneous injection; and H (3 mg/M²/d), D 1-7, subcutaneous injection. Case 2 was treated with the MAH regimen on D 47 and D80. The doses and methods were as above. On D115, he was treated with IDA (10mg/M²/ D1-3); intravenous infusion; once a day. The dosage and usage of the ara-C and H were the same as before. On D145, bone marrow cell morphology was evaluated, residual lesions were detected by flow cytometry, and WT1 gene copy number was detected by molecular biological techniques (See Methods). On D175, he was treated with HD ara-C (2.0 g/M²/d), D1, 3, 5 and 7; q12h. The dose and usage of HD ara-C were the same as above. On D205, HD ara-C dose and usage were the same as above: Vp-16 (100 mg/M²/d), D1-5; intravenous infusion. On D 235, he received HD ara-C (3.0g/M²/d); D1, 3, 5, 7; q12h; the dose and usage were the same as above. During D265-730, 6-MP [50 mg/M²/d (D1-21)] plus low-dose ara-C (40mg/M²) were given. D1-4 (D22-28) maintenance therapy: Bone marrow cell morphology was returned one year after drug discontinuation, residual lesions were detected using flow cytometry, and WT1 gene copy number was detected by molecular biological tools (See methods).

OUTCOME AND FOLLOW-UP

Bone marrow smear: Case 1 showed active bone marrow with nucleated cell hyperplasia. Case 2 originally had granulocyte at 1.0%, and abnormal early young granulocyte at 83.0% and 85.0%, respectively. The cytoplasm was bulky and filled with azure particles. Plasma particles were visible both inside and outside some cells, with less outside the cells. Round or oval nucleus, coarse chromatin, and indistinct nucleoli were observed. Acute promyelocytic leukemia is shown in Figure 1.

Karyotype analysis

The following results were revealed: Case 1: 46XY, i(17)(q10)[9]/46, XY[11], long equi arm of chromosome 17; Cases 2: 46XY, Add(14)(P11), i(17)(q10)[4]/46, XY[1], a short arm of chromosome 14 with an additional fragment of unknown origin and a long arm of chromosome 17, as shown in Figure 2.

Fully-instrumented submersible housing detection

Case 1: The nuclear in situ hybridization (nuc ish) (PML × 2, RARA × 3) (180/400) showed no fusion signal by PML/RARA translocation probe, and the copy number of RARA (located at 17q21) site was indistinct. Case 2: The nuc ish (PML × 2, RARA × 2) showed no abnormal signal in the PML/RARA locus, and the copy number of RARA (located at 17q21) site increased, accounting for about 45%.

Immune typing

Abnormal cells were accounted for 88% in Case 1 and 78% in Case 2. Flow cytometric analysis on CD45/SSC dot plot showed that CD9, CD13, CD33, and CD38 were mainly expressed in all analyses, while CD64, CD123, and MPO were only expressed in some analyses. CD58 was expressed in case 1 and CD15 was expressed in case 2, as shown in Figure 4. Molecular biological detection: PML/RARA, PLZF/RARa, NPM/RARa, STAT5b/RARa, NuMA1/RARa, PKRKA/RARa, and FIPIL1/RARa fusion-gene tests showed negative results.

Detection of gene (exon) variation related to myeloid and gonorrhea hematologic malignancies was performed by targeted capture method. Mutation sites were clearly associated with the disease, and all of them had mutations of WT1 (Wilms Tumor 1). Case 1 WT1: NM_024426: exon9:c.G1367C:p.C456s; mutation frequency 49.2%. Case 2 WT1: NM_024426:exon1:c.410_413del:p.137_138del; mutation frequency 100%. Case 1 with EP300 (E1A Binding Protein p300) mutations: NM_001429: exon51:c.C5449T:p.Q1817X; mutation frequency 72.1%.
For case 1, the following mutation sites might be associated with the disease: (1) USP6 (NM_004505:exon12:c.854delG:p.W285fs) was a frameshift mutation, with a mutation frequency of 32.6%; (2) NUTM2G (NM_001170741:exon7:c.C2102T:p.701L) was a missense mutation, with a mutation frequency of 78.8%.

For case 2, the following mutation sites might be associated with the disease: (1) TAL1 (T-Cell Acute Lymphocytic Leukemia gene) mutation (NM_003189:exon6:c.821_822insGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG
no nucleolus. Residual leukemia detection revealed no immunophenotypic abnormal cell population (residual leukemia cells < 10⁴); complete remission occurred. Up to now, the drug has been discontinued for 1 year, and the clinical, morphological, and flow cytometry results continued to show complete remission. However, the copy number of the WT1 gene was 1010-1087, and the expression rate was 51.95%–55.29%, which indicated the risk of recurrence, and allogeneic hematopoietic stem cell transplantation was necessary.

**DISCUSSION**

APL is a rare subtype of AML and has different morphological and immunological characteristics compared with other myeloid leukemia cells. Karyotype t (15;17) is a unique chromosome translocation in APL. At the molecular level, PML/RARα fusion gene is formed by translocation of PML gene at 15q and RARα gene at 17q. Therefore, it is a highly specific cytogenetic marker for this type of leukemia. In this case study, the phenotype of 2 children showed typical APL characteristics, especially some cells had inner and outer plasma membrane, with thick azinophilus granules (Figure 1). Immunophenotypic markers mainly included CD9, CD13, CD33, CD38 (Figure 2), and CD64, CD123, MPO were also expressed in case 1. In addition, case 1 also had the expression of CD15, which was consistent with the immunophenotype of APL[16,17] and the isolated i(17)(q10) AML with similar APL morphology. Previously, 4 isolated i(17)(q10) cases were reported, including 2 children[13,14], 1 adult[15], 1 case without age information[18], and 3 cases with M3 (APL) FAB classification. There were no t(15;17) and PML-RARα fusion gene detected and patients had no responses to ATRA treatment[15]. One case did not respond to chemotherapy and the survival time was less than 1 mo[14]. The other 2 cases did not mention prognosis[13,19]. In this study, there were 2 cases examined, case 1 was isolated i(17)(q10), case 2 was isolated i(17)(q10) add(14)(p11). The (15;17) was not present, and PML-RARα fusion gene was not detected by Fully-instrumented submersible housing and second-generation sequencing, which rendered ATRA and As₂O₃ combined chemotherapy ineffective. Case 1 survived 5.5 mo. Case 2 achieved sustained complete remission after intensive chemotherapy with acute non-eluting regimen. The difference might not be related to isolated i(17)(q10) cases were reported, including 2 children[13,14], 1 adult[15], 1 case without age information[18], and 3 cases with M3 (APL) FAB classification. There were no t(15;17) and PML-RARα fusion gene detected and patients had no responses to ATRA treatment[15]. One case did not respond to chemotherapy and the survival time was less than 1 mo[14]. The other 2 cases did not mention prognosis[13,19]. In this study, there were 2 cases examined, case 1 was isolated i(17)(q10), case 2 was isolated i(17)(q10) add(14)(p11). The (15;17) was not present, and PML-RARα fusion gene was not detected by Fully-instrumented submersible housing and second-generation sequencing, which rendered ATRA and As₂O₃ combined chemotherapy ineffective. Case 1 survived 5.5 mo. Case 2 achieved sustained complete remission after intensive chemotherapy with acute non-eluting regimen. The difference might not be related to isolated i(17)(q10) add(14)(p11), which was speculated to contribute to the transport of chemotherapeutic drugs. Similar studies have not been reported on leukemia patients, and the underlying specific mechanism needs further exploration. However, with the high expression of WT1 gene, the risk of recurrence is still very high[30]. Further clinical follow-up is required, and hematopoietic stem cell transplantation is necessary. However, this case was different from occult APL and APL with i(17)(q10) and PML-RARα fusion gene, for which the ATRA and As₂O₃ combined chemotherapy was effective[2,18].

Patients with myeloid tumor i(17)(q10) are mostly MDS/MPO+ patients with a chronic history, and often have pathological hematopoiesis in granulocyte, erythrocyte, and megakaryocyte lines, with an average of 3 gene mutations, mainly ASXL1, SRF2, and SETP1[8,9]. In this study, 2 patients had a short course of the disease, with no history of MDS/MPO+, and no erythrocyte or megakaryocyte pathological hematopoiesis except granulocyte lineage, which was similar to a 27-year-old female APL-like AML patient with a short course of the disease, having no chronic history and multi-family pathological hematopoiesis[15].

Gene mutations in these APL-like AML cases were reported for the first time, and there were 5 mutations in case 1, including WT EP300 c.854delg: P w285fs frame-shift mutation and C.C2102T: P
701L missense mutation. WT1, TALI, TTN, and DDX11 mutations were found in case 2. Both cases had WT1 gene mutations, which were consistent with the characteristics of i(17)(q10) gene mutations (0-6) in MDS/MPO+ patients, but the gene mutation points were completely different. Therefore, case with i(17)(q10) was clinically diagnosed. The morphological diversity was probably due to different mutation patterns, and the number and order of the mutations might play a key role[8]. Therefore, both morphologic and immunological manifestations of APL were found in 2 children without t(15;17) and PML-RARA fusion-gene expression. Though preliminary diagnosis of AML morphologically similar to APL[15] were made for both children, the treatment failed in case 1, and case 2 with add(14)(p11) achieved sustained complete remission after chemotherapy, which might be related to the different gene mutation points.

Through literature review, 6 patients with i(17)(q10) have been known (including 2 in this group), 5 morphologically similar to AML, 1 without FAB classification mentioned[13], 5 with isolated TYPE i(17)(q10), 1 with add(14)(p11), and 3 patients (including 2 in this group) had CD33 immunophenotype
Table 1 Motivational interviewing case management genotyping of the cases

| Number | Age | Sex | FABtyping | Karyotype | Immunological phenotype | Genemutation | Therapeutic reaction | Prognosis | Ref. |
|--------|-----|-----|-----------|-----------|-------------------------|--------------|---------------------|-----------|-----|
| 1      | 27  | F   | M3        | i(17)(q10) | CD33+/CD13+/ MPO      | PML-RARα (-) | Retinoic acid (-)   | Die (survival 1 mo) | Yan et al [15], China |
| 2      | 10  | M   | M3        | i(17)(q10) | -                      | -            | NR                  | Die (survival < 1 mo) | Bernstein et al[14], South Africa |
| 3      | Child | F | -         | i(17)(q10) | -                      | -            | -                   | -         | Raimondi et al[13], Mexico |
| 4      | -   | -   | M3        | i(17)(q10) | -                      | -            | -                   | -         | Becher et al[19] |
| 5      | 3   | M   | M3 (Case 1) | i(17)(q10) | CD9/CD13/CD33/CD38/CD64/CD123/CD58/MPO | WT1/EP300/C854delG: P w285fs Frame shiftC2102T: P.701LMissense | - | - | Wen JQ, China |
| 6      | 12  | M   | M3 (Case 2) | i(17)(q10) Add(14) (p11) | CD9/CD13/CD33/CD38/CD64/CD123/CD15/MPO | WT1/TAL1/TTN/DDX11 | CR 36 months, WT1 copy: 1010-1087 | - | Wen JQ, China |

F: Female; M: Male.

with CD3 MPO expression[15]. Using existing genetic and molecular biological techniques, t(15;17) among the 6 patients with PML-RARα fusion gene were not detected, 3 patients failed to respond to ATRA-As₂O₃ and chemotherapy and died (survival shorter than 5.5 mo), 1 patient achieved sustained complete response after chemotherapy, and 2 patients did not show prognosis[13,18].

Morphology, immunology, chromosomal karyotype, and molecular biological genotyping of 6 cases with i(17)(q10) in different periods and their prognosis are shown in Table 1.

CONCLUSION

APL-like AML with i(17)(q10) has morphological and immunological characteristics similar to APL, without t(15;17) and PML-RARα fusion gene expression. ATRA-As₂O₃ and chemotherapy were not effective in treating the patients, with short survival period. If a chromosomal addition occurred, a sustained complete remission should be achieved and related clinical manifestations should be revealed. It is necessary to further strengthen the molecular biological study and collect a large number of cases to provide better treatment strategies.

ACKNOWLEDGEMENTS

We thank the Hematological Tumor Molecular Special Detection Technology Research Center of Kindstar Global (Wuhan) for its technological support.

FOOTNOTES

Author contributions: Yan HX and Wen JQ contributed to conception and design of the study; Yan HX and Zhang WH are the co-first author; Zhang WH organized the database; Yan HX wrote the first draft of the manuscript; all authors contributed to manuscript revision, read, and approved the submitted version.

Supported by Shaanxi Natural Science Foundation, No. 2020SF-004.

Informed consent statement: Consent was obtained from relatives of the patient for publication of this report and any accompanying images.

Conflict-of-interest statement: The authors declare that they have no conflicts of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Hong-Xia Yan: 0000-0001-7272-716X; Wei-Hua Zhang: 0000-0002-4579-3492; Jin-Quan Wen: 0000-0001-9202-6598; Yan-He Liu: 0000-0001-5141-8122; Bao-Juan Zhang: 0000-0002-1534-9622; A-Duo Ji: 0000-0001-6328-6227.

S-Editor: Xing YX
L-Editor: A
P-Editor: Xing YX

REFERENCES

1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937-951 [PMID: 19357394 DOI: 10.1182/blood-2009-03-209262]
2. Meza Espinoza JP, Judith Picos Cárdenas V, Gutiérrez-Angulo M, González García JR. Secondary chromosomal changes in 34 Philadelphia-chromosome-positive chronic myelocytic leukemia patients from the Mexican West. Cancer Genet Cytogenet 2004; 148: 166-169 [PMID: 14734233 DOI: 10.1016/s1046-4608(03)00283-5]
3. Wang W, Tang G, Cortes JE, Liu H, Ai D, Yin CC, Li S, Khoury JD, Bueso-Ramos C, Medeiros LJ, Hu S. Chromosomal rearrangement involving 11q23 locus in chronic myelogenous leukemia: a rare phenomenon frequently associated with disease progression and poor prognosis. J Hematol Oncol 2015; 8: 32 [PMID: 25888368 DOI: 10.1186/s13045-015-0128-2]
4. Sheth FJ, Sheth JJ, Desai C. Case of near triploidy with i(17)(q10) in blast crisis CML. Cancer Genet Cytogenet 2006; 164: 177-178 [PMID: 16434327 DOI: 10.1016/j.cancergen.2005.07.022]
5. Garay CA, Al-Saleem T, Testa JR, Smith MR. Coexisting myelodysplasia and myeloproliferative features in a single clone containing 5q-, Ph and i(17q). Leukemia 2012; 36: 1649-1650 [PMID: 22337470 DOI: 10.1136/leukemia.2011.200698]
6. Nishida H, Ueno H, Park JW, Yano T. Isochromosome i(17q) as a sole cytogenetic abnormality in a case of leukemic transformation from myelodysplastic syndrome (MDS)/myeloproliferative diseases (MPD). Leuk Res 2008; 32: 1325-1327 [PMID: 18164759 DOI: 10.1016/j.leukres.2007.11.021]
7. Kanagal-Shamanna R, Bueso-Ramos CE, Barkoh B, Lu G, Wang S, Garcia-Manero G, Vadhan-Raj S, Hoehn D, Medeiros LJ, Yin CC. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Cancer 2012; 118: 2879-2888 [PMID: 22038701 DOI: 10.1002/cncr.26537]
8. Meggendorfer M, Haferlach C, Zenger M, Maciejewski JK, Kern W, Haferlach T. The landscape of myeloid neoplasms with isochromosome 17q discloses a specific mutation profile and is characterized by an accumulation of prognostically adverse molecular markers. Leukemia 2016; 30: 1624-1627 [PMID: 26859077 DOI: 10.1038/leu.2016.21]
9. Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C, Haferlach T, Schnittger S. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASX1 and CBL mutations. Leukemia 2013; 27: 1852-1860 [PMID: 23628959 DOI: 10.1038/leu.2013.133]
10. Berger R, Le Coniat M, Derré J, Vecchione D, Jonveaux P. Cytogenetic studies in acute promyelocytic leukemia: a survey of secondary chromosomal abnormalities. Genes Chromosomes Cancer 1999; 31: 337-332 [PMID: 1797083 DOI: 10.1002/gcc.2870030503]
11. Heim S, Mitelman F. Secondary chromosome aberrations in the acute leukemias. Cancer Genet Cytogenet 1986; 22: 331-338 [PMID: 3460687 DOI: 10.1016/0165-4608(86)90025-7]
12. Kim MJ, Yoon HS, Cho SY, Lee HJ, Suh JT, Lee J, Yoon HJ, Lee WI, Park TS. ider(17)(q10)(t15;17) associated with relapse and poor prognosis in a pediatric patient with acute promyelocytic leukemia. Cancer Genet Cytogenet 2010; 116: 121-126 [PMID: 20682396 DOI: 10.1016/j.cancergen.2010.05.007]
13. Raimondi SC, Chang MN, Ravindranath Y, Behm FG, Greisik MV, Steuber CP, Weinstein HJ, Carroll AJ. Cytogenetic studies in acute promyelocytic leukemia: a survey of secondary chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study–POG 8821. Blood 1999; 94: 3707-3716 [PMID: 10572083]
14. Bernstein R, MacDougall LG, Pinto MR. Chromosome patterns in 26 South African children with acute lymphoblastic leukemia (ANLL). Cancer Genet Cytogenet 1984; 11: 199-214 [PMID: 692340 DOI: 10.1016/0165-4608(84)90114-6]
15. YC D, BZ R, Y L. Clinical significance of isolated isochromosome 17q in hematologic tumors. 16. Ren F, Zhang N, Xu Z, Xu J, Zhang Y, Chen X, Tan Y, Chang J, Wang H. The CD9+ CD11b+ HLA-DR+ immunophenotype can be used to diagnose acute promyelocytic leukemia. Int J Lab Hematol 2019; 41: 168-175 [PMID: 30315692 DOI: 10.1111/ijlh.12929]
17 Gong JY, Li YY, Li CW, Wang YS, Liu Y, Wang C, Ru K, Mi YC, Wang JX, Wang HJ. [Application of immunophenotypic analysis and molecular genetics in the diagnosis of acute promyelocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi 2019; 40: 288-293 [PMID: 31104439 DOI: 10.3760/cma.j.issn.0253-2727.2019.04.005]

18 Lee GY, Christina S, Tien SL, Ghafar AB, Hwang W, Lim LC, Lim TH. Acute promyelocytic leukemia with PML-RARA fusion on i(17q) and therapy-related acute myeloid leukemia. Cancer Genet Cytogenet 2005; 159: 129-136 [PMID: 15899384 DOI: 10.1016/j.cancergencyto.2004.09.019]

19 Becher R, Carbonell F, Bartram CR. Isochromosome 17q in Ph1-negative leukemia: a clinical, cytogenetic, and molecular study. Blood 1990; 75: 1679-1683 [PMID: 2328318 DOI: 10.1182/blood.V75.8.1679.1679]

20 Krauth MT, Alpermann T, Bacher U, Eder C, Dicker F, Ulke M, Kuznia S, Nadarajah N, Kern W, Haferlach C, Haferlach T, Schnittger S. WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups. Leukemia 2015; 29: 660-667 [PMID: 25110071 DOI: 10.1038/leu.2014.243]
